Wednesday, December 17, 2025 12/17/2025

Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines

Award Number: R37CA266344
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/09/2021
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines - PROJECT SUMMARY Despite the impressive activity of chimeric antigen receptor (CART) T cell therapy in the treatment of B-cell malignancies, the therapy is limited by the development of cytokine release syndrome (CRS) and neurotoxicity, as well as by lower rates of durable responses. While CRS is related to extreme elevation of cytokines associated with T cell expansion, the exact etiology of neurotoxicity is unknown and no options for treatment of neurotoxicity are available. It has, however, become apparent that inhibitory myeloid cells and cytokines contribute to both CART cell toxicities and resistance. We have identified granulocyte-macrophage colony- stimulating factor (GM-CSF) as a dominant driver for CART cell toxicity and inhibition of their functions. Our robust preclinical data indicate that GM-CSF inhibition reduces monocyte activation, enhances CART cell functions and prevents the development of both CRS and neurotoxicity in a novel xenograft model for CART cell-associated toxicities. Our additional studies suggest that GM-CSF disruption in CART cells ameliorates their apoptosis, independent of its effect on myeloid cells. These findings were corroborated when we utilized GM-CSF depletion as a therapeutic strategy in patients with cytokine storm and severe Coronavirus Disease 2019, COVID-19. Based on this work, a Phase 1/2 multi-center study of GM-CSF neutralization after CART19 cell therapy was launched. Our central hypothesis is that depletion of GM-CSF results in modulation of myeloid cell behavior, amelioration of CART cell activation, reduction of CART cell associated toxicities, and enhancement of their efficacy. We will leverage our laboratory tools, novel preclinical models, and samples from this clinical trial to test our hypothesis. In Aim 1 of this project, we will examine the interactions between GM-CSF and monocytes after CART cell therapy. In Aim 2 of this project, we will study the effect of GM-CSF directly on CART cells, and Aim 3 will test how these changes affect toxicity and efficacy of CART19 cell therapy in the novel Phase 1/2 clinical trial. Completion of these Aims will identify novel insights into the toxicity and activity of CART cells and will develop a new strategy to prevent CART cell associated neurotoxicity and CRS, potentially enabling the outpatient administration of CART cell therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $554,542 )
2026	2026	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	5	12/5/2025	NON-COMPETING CONTINUATION	$554,542
														Subtotal = $554,542

Issue Date FY: 2025 ( Subtotal = $616,157 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	4	1/23/2025	NON-COMPETING CONTINUATION	$554,542
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	001	4	2/12/2025	NON-COMPETING CONTINUATION	$0
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	002	4	6/16/2025	NON-COMPETING CONTINUATION	$61,615
														Subtotal = $616,157

Issue Date FY: 2024 ( Subtotal = $600,395 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	002	3	4/17/2024	NON-COMPETING CONTINUATION	$31,600
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	001	3	12/15/2023	NON-COMPETING CONTINUATION	$568,795
2024	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	2	11/21/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $600,395

Issue Date FY: 2023 ( Subtotal = $1,094,433 )
2023	2023	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	2	11/22/2022	NON-COMPETING CONTINUATION	$568,868
2023	2023	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	001	2	3/15/2023	NON-COMPETING CONTINUATION	$50,565
2023	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	002	2	9/18/2023	SUPPLEMENT FOR EXPANSION	$475,000
														Subtotal = $1,094,433

Issue Date FY: 2022 ( Subtotal = $606,332 )
2022	2022	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Treatment Research	000	1	12/9/2021	NEW	$606,332
														Subtotal = $606,332

Grand Total All Awards = $3,471,859

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines

Award Number: R37CA266344

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/09/2021

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer